Atosiban: a comprehensive approach to preterm labour management

Preterm birth (PTB) continues to be a leading cause of neonatal mortality and long-term complications globally, reinforcing the need for effective and safe tocolytic treatments. Atosiban, an oxytocin receptor antagonist, has emerged as a pivotal intervention for managing spontaneous preterm labour (sPTL) due to its targeted mechanism and favourable safety profile. This is especially critical in regions like India, where there is a significant therapeutic gap in the availability of effective, safe, and cost-efficient tocolytic agents. Dosing regimens for Atosiban include a full course (48 hours), a brief course (14 hours), and a single bolus dose. The brief and bolus regimens are particularly advantageous in settings that prioritize shorter hospital stays or outpatient management, offering a more convenient and cost-effective approach. These regimens also provide the flexibility of repeat treatments if necessary, enhancing patient care adaptability. Extensive clinical studies have validated Atosiban's efficacy and safety across its various dosing regimens. Although Atosiban has a high initial cost compared to its alternatives, such as β2-agonists and calcium channel blockers, its superior safety profile and targeted action result in fewer maternal and fetal side effects, thereby reducing overall healthcare costs. The ability to manage sPTL with shorter regimens alleviates the strain on healthcare resources and minimizes the need for intensive neonatal care, with significant cost savings. Overall, Atosiban represents a valuable therapeutic option for managing preterm labour. Its proven efficacy, safety, and cost-effectiveness make it a preferred choice for tocolysis, particularly in high-risk pregnancies like those with diabetes or cardiac issues.